Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Agena Bioscience, Inc.. (7/24/18). "Press Release: Agena Announces MassARRAY Technology Selected for Participation in CANCER-ID Consortium". San Diego, CA.

Region Region EU (European Union)
Organisation Organisation Agena Bioscience Inc.
  Group Agena Bioscience (Group)
Products Product MassARRAY® system
  Product 2 liquid biopsy
Index term Index term Innovative Medicines Initiative–Agena Bioscience: MassARRAY Technology, 201807– collab use of MassArray system in CANCER-ID Consortium
Person Person Dansky, Peter M. (Agena Bioscience 201407– CEO before Life Technologies + Applied Biosystems + Arcturus + Affymetrix)
     


Agena Bioscience, a global provider of molecular testing solutions, announced today that it has been selected for participation in the CANCER-ID Consortium. Agena’s MassARRAY® System will support mutation detection from liquid biopsy samples as part of the consortium’s key work packages in lung cancer and breast cancer.

“We are honored to have been selected to participate in the CANCER-ID consortium” said Peter Dansky, Chief Executive Officer of Agena Bioscience. “With the MassARRAY System, we look forward to contributing the assay sensitivity, rapid workflow and low cost per test necessary to support the goals of the consortium in bringing liquid biopsy into personalized medicine.”

CANCER-ID is a European consortium supported by Europe’s Innovative Medicines Initiative (IMI). With partners from 13 countries, the goal of the consortium is to establish standard protocols for and the clinical validation of the use of blood-based biomarkers for cancer. It brings together internationally recognized experts in CTC’s, ctDNA and cfmiRNA who are committed to establishing clinical utility of liquid biopsy to monitor efficacy of treatment and potentially improve treatment options for patients with cancer.

“The development of robust validated assays is required to bring liquid biopsy into the clinic”, says Prof. Klaus Pantel from the University Medical Center Hamburg-Eppendorf and a Co-Coordinator of CANCER-ID. “From our experience, MassARRAY has the sensitivity necessary to pick up mutations that are relevant to therapeutic decisions in NSCLC patients.”


About Agena Bioscience

Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.


Media Contact:

Agena Bioscience
Mickie Henshall
(858) 882-2707
mickie.henshall@agenabio.com

   
Record changed: 2018-08-22

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Agena Bioscience (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px




» top